

RECOMBINANT *SACCHAROMYCES CEREVISIAE* AS NEW DRUG DELIVERY SYSTEM TO GUT: IN VITRO VALIDATION AND ORAL FORMULATION

STÉPHANIE BLANQUET AND MONIQUE ALRIC

Université d'Auvergne, Clermont-Ferrand, France

Contents

- 1 Engineered Microorganisms as Delivery Vectors to Human Gastrointestinal Tract
 - 1.1 What is the “Biodrug” Concept?
 - 1.2 Medical Applications
 - 1.3 Choice of Candidate Host Microorganisms
 - 2 Evaluation of Scientific Feasibility of Biodrug Concept Using Yeast as Vector
 - 2.1 Approach
 - 2.2 Yeast Survival Rate in Simulated Gastrointestinal Conditions
 - 2.3 Yeast Heterologous Activity in Simulated Gastrointestinal Conditions
 - 2.4 Conclusion
 - 3 Oral Formulation of Recombinant Yeasts
 - 3.1 Freeze Drying of Recombinant Model Yeasts
 - 3.2 Immobilization of Recombinant Model Yeasts in Whey Protein Beads
 - 4 General Conclusion and Future Developments
- References

1 ENGINEERED MICROORGANISMS AS DELIVERY VECTORS TO HUMAN GASTROINTESTINAL TRACT

1.1 What Is the “Biodrug” Concept?

The development of recombinant deoxyribonucleic acid (DNA) technology has allowed the emergence of novel applications such as drug production directly in the

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing
Edited by Shayne C. Gad
Copyright © 2010 John Wiley & Sons, Inc.